

### This week in techniques

| Approach                                  | Summary  | Licensing status  | Publication and contact information  |
|---|--|---|--|
| <b>Drug Platforms</b>                     |  |   |  |
| NF-κB pathway modulation for gene therapy | <p>Studies in cell culture and in mice suggest that modulating NF-κB signaling could improve the safety and efficacy of gene therapy. In HeLa cells transduced with a gene encoding a fluorescent protein, an NF-κB activator increased protein expression about 25-fold compared with no treatment (<math>p &lt; 0.001</math>). Also in mice, pretreatment with an NF-κB pathway inhibitor lowered induction of an inflammatory response compared with no treatment. Next steps could include evaluating NF-κB inhibitors in canines and nonhuman primates.</p> | <p>Work on NF-κB pathway modulation unpatented; patent application filed covering related technology for tyrosine-mutant adeno-associated viral (AAV) vectors; AAV vectors available for licensing<br/> <b>Contact:</b> Elizabeth Garami, University of Florida, Gainesville, Fla.<br/>                     phone: 352-392-8929<br/>                     e-mail: <a href="mailto:egarami@ufl.edu">egarami@ufl.edu</a></p> | <p>Jayandharan, G.R. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online Feb. 14, 2011; doi:10.1073/pnas.1012753108<br/> <b>Contact:</b> Arun Srivastava, University of Florida College of Medicine, Gainesville, Fla.<br/>                     e-mail: <a href="mailto:aruns@peds.ufl.edu">aruns@peds.ufl.edu</a></p> |
|   | <p><b>SciBX 4(9); doi:10.1038/scibx.2011.264</b><br/>                     Published online March 3, 2011</p>   |   |  |